Certis Oncology showcases recently launched AI/ML platforms for cancer therapeutics development and personalized medicine.
Presentation highlights AI’s transformative role in precision medicine, features CertisAI Predictive Oncology Intelligence™ and CertisOI Assistant™.
Certis Oncology Solutions, a precision oncology and translational science company, showcased today its latest advancements in AI/ML at the Precision World Medicine Conference in Santa Clara, California.
Certis President and CEO, Peter Ellman, presented “Predictive Oncology Intelligence: Revolutionizing Cancer Research with AI-Enabled Precision Oncology,” as part of the event’s coverage of the rapidly expanding role of artificial intelligence in precision medicine. Ellman discussed the various ways the company’s patent-pending predictive AI/ML platform, CertisAI™, helps close the translation gap in cancer therapeutics development via AI-enabled drug response predictions, better informed biomarker strategy, and data-driven decision-making.
“We’ve been talking about personalized medicine for decades now, but we’ve made little progress for patients. Nine out of ten investigational cancer therapies still fail in clinical trials. And despite all that we now know about cancer at a molecular level, fewer than 10% of patients derive meaningful clinical benefit from even the most advanced genomics-informed treatment,” said Ellman. “In 2025, we have tools to change that. Multivariate computational algorithms, together with faster, lower-cost computing power, are quickly transforming the way we approach drug development and how we think about individualizing care.”
During Ellman’s presentation, conference attendees were treated to an interactive demonstration of CertisOI Assistant™, a recently launched generative AI tool that accelerates research workflows and democratizes the evaluation of complex datasets. The CertisOI Assistant works as a natural language intermediary for analyzing the genomic and drug sensitivity characterization data associated with thousands of cancer research models, including Certis’ patient-derived xenograft (PDX) models as well as public cancer cell lines from the Cancer Cell Line Encycolopedia (CCLE).
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
